ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

ORI Final Findings Of Scientific Misconduct

September 16, 1994

In Brief: NCI Seeking Industry Support Again For Summer Program Congress Oks Smokeless Tobacco Bill

February 14, 1986

In Brief: NCCR Presents Gold Medal To Sen. Karkin; DCT Recruits Okunieff For Radiation Oncology

February 26, 1993

FDA Seeks Consumers For Advisory Committees.

November 23, 2001

Cancer Program Advocates Seek $170 Mil. Above President’s Budget, Vow To Close Bypass Gap

May 8, 1992

Komen Foundation Offer Fellowships

February 9, 1996